Tikkunlev Therapeutics
TikkunLev Therapeutics is on a mission to revolutionize the treatment of heart failure by targeting the underlying biology of failing heart muscle. Founded on the pioneering research of Professor Robin Shaw M.D, Ph.D, our lead program, TLT-101, is a precision therapy that targets the underlying protein trafficking defects in heart failure. Extensive preclinical data demonstrate an unprecedented efficacy and safety profile with our therapeutic approach. TLT-101 is in IND-enabling development for non-ischemic dilated cardiomyopathy (DCM), a severe and progressive disease that is a leading cause of heart failure. With cardiovascular disease remaining the leading global cause of death and 1 in 4 people expected to develop heart failure, our innovative approach aims to repair the heart and transform lives.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Tikkunlev Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Tikkunlev Therapeutics
1 distinct titles indexed · top 1 shown.
- 1wyss institute at harvard university
Sign up to unlock all 1 contacts at Tikkunlev Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Tikkunlev Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.